Abstract
Background Patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) report difficulty with sleep.MethodsWe examined the effect of omalizumab on sleep-related outcomes during 3–6 months omalizumab or placebo treatment and a 16-week follow-up period within three Phase III double-blind randomized placebo-controlled pivotal trials in CIU/CSU: ASTERIA I, ASTERIA II, and GLACIAL. Sleep quality was assessed in all three studies using sleep-related questions included in an electronic diary, the Chronic Urticaria Quality of Life Questionnaire, and the Medical Outcomes Study Sleep Scale. Score changes from baseline in the treatment arms were compared with that in the placebo arm and adjusted for baseline score and weight. We also examined correlations of sleep scores at baseline, week 12, and week 24 and the slopes of change between sleep and itch and hive.ResultsPatients treated with omalizumab reported a larger reduction in sleep problems than those in the placebo arm; omalizumab 300 mg demonstrated the greatest improvement on all sleep components among all treatment arms. The largest reduction in sleep problems was reported within the first 4 weeks of therapy. After treatment discontinuation, sleep quality worsened. Sleep scores demonstrated moderate-to-strong correlation between them, and the change in sleep scores was associated with changes in itch and hives.ConclusionsImprovement in sleep was reported after the first dose of omalizumab. Sleep continued to improve throughout the active treatment period. Patients receiving omalizumab 300 mg achieved greater improvement in sleep than those in other treatment arms.Trial registration ClinicalTrials.gov, NCT01287117 (ASTERIA I), NCT01292473 (ASTERIA II), and NCT01264939 (GLACIAL)Electronic supplementary materialThe online version of this article (doi:10.1186/s13601-016-0120-0) contains supplementary material, which is available to authorized users.
Highlights
Patients with chronic idiopathic/spontaneous urticaria (CIU/chronic spontaneous urticaria (CSU)) report difficulty with sleep
We investigated the following research question: to what extent do sleep outcomes improve in Chronic idiopathic urticaria (CIU)/CSU patients treated with omalizumab during 3 to 6 months within these three pivotal studies?
Patients with CIU/CSU in all treatment arms experienced improvement in sleep at week 12 compared with Baseline for all sleep measures (Table 2)
Summary
Patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) report difficulty with sleep. Gimenéz‐Arnau et al Clin Transl Allergy (2016) 6:32 adequate sleep [7,8,9,10,11]. Omalizumab is a humanized anti-immunoglobulin E antibody indicated for CIU/CSU in adults and adolescents who remain symptomatic despite H1-antihistamine treatment [13], as reported in the pivotal clinical studies [14,15,16]. Phase III omalizumab CIU/CSU clinical studies collected sleep quality data via patient-reported outcome measures. We investigated the following research question: to what extent do sleep outcomes improve in CIU/CSU patients treated with omalizumab during 3 to 6 months within these three pivotal studies?
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
